March 25, 2013 /PRNewswire/ --
Biomaterials Market [By Products (Polymers, Metals, Ceramics, Natural Biomaterials) & Applications (Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Ophthalmology, Neurology Disorders)] - Global Forecasts To 2017 analyzes and studies the major market drivers, restraints, and opportunities in
Asia, and Rest of the World.
- 220 market data tables
- 33 figures
- 504 Pages and an in-depth Table of Content on " Biomaterials Market"
Early buyers will receive 10% customization on this report.
This report studies the global biomaterial market over the forecast period of 2012-2017. The global market for biomaterials is estimated at
in 2012 and is poised to grow at a CAGR of 15% from 2012 to 2017 to reach
The global biomaterial market is broadly segmented into two categories, by type and by application. The global biomaterials market, by type, is broadly categorized into metals, ceramics, polymers, and natural biomaterials. The biomaterial applications market is broadly segmented into orthopedic, cardiovascular, neurological, dental, tissue engineering, wound healing, plastic surgery, ophthalmology and other applications such as gastrointestinal, urinary, bariatric surgery, and drug delivery system. In 2012, the cardiovascular biomaterial segment contributed 34.5% to the global biomaterial market, followed by the orthopedic segment. Plastic surgery and wound healing applications are expected to witness the highest growth in the coming years.
The biomaterial polymers market is expected to show the highest growth at a CAGR of 22.1% (2012-2017) due to tremendous ongoing research for the development of biodegradable and bio-compatible polymeric biomaterial and its use in a wide range of applications.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts